for all the complaining i have done lately about C
Post# of 148173
https://onlinelibrary.wiley.com/doi/full/10.1111/imr.12897
These guys conducted a review of gentics and covid for the purpose of identifying genetic mutations that might be causative in covid.
And it never occurrs to them to check and see if CCR5delta32 is protective in covid.
Hilariously, they explicitly identify CCR5delta32 protectivity in HIV as an example of how genetics can influence disease.
But it never occurrs to them to check CCR5delta32 protectivity in covid!!!!
Its new and all and the article was published in July so possibly they never heard of leronlimab. Probably no data on CCR5delta32 and covid at that time anyways.
Perhaps I am to blame as much as anyone else. I knew nine months ago that CCR5delta32 genetics could play a role in covid.
Had I asked CYDY, I am sure I would have had at least a chance at persuading them to add CCR5 DNA test to every patient they treat.
The combo of RO testing and CCR5 genetics could recast leronlimab as a genetics treatment.
The p-values on genetics treatment are always like 0.0000001 because there is no chance involved.